Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05972733Phase 2Completed

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

Role: lead

NCT05281094Phase 2Terminated

Efficacy and Safety of Two Doses of HIL-214 in Children

Role: lead

NCT06007781Phase 1Completed

Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants

Role: lead

NCT05836012Phase 2Completed

Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

Role: lead

All 4 trials loaded